Spatial Genomics

Executive Summary

Spatial Genomics is a pioneering spatial genomics company based in Los Angeles, founded in 2019. The company has developed the GenePS platform, which leverages sequential fluorescence in situ hybridization (seqFISH) technology to enable highly multiplexed, multi-omic spatial analysis of RNA, DNA, and proteins within intact cells and tissues. This powerful approach allows researchers to visualize and quantify biomolecules in their native spatial context, offering unprecedented insights into cellular organization, disease mechanisms, and tissue heterogeneity. Spatial Genomics' technology addresses a critical gap in genomics by preserving spatial information that is lost in traditional bulk sequencing methods. The company's platform is designed for a wide range of applications, including cancer research, neuroscience, developmental biology, and drug discovery. By enabling spatially resolved multi-omics, Spatial Genomics is positioned to become a key player in the rapidly growing spatial biology market, which is projected to reach multi-billion dollar valuations. The company's ability to offer a fully integrated solution—from sample preparation to data analysis—gives it a competitive edge over other spatial technologies like MERFISH and Visium. Despite being at an early stage, Spatial Genomics has the potential to drive major advances in precision medicine and basic research.

Upcoming Catalysts (preview)

• Q3 2026Launch of enhanced GenePS platform with higher throughput and multiplexing capability70% success
• TBDStrategic partnership with a major pharmaceutical company for oncology drug discovery60% success
• TBDCompletion of Series A funding round to scale commercialization80% success